Metformin Hydrochloride Taw Pharma (Ireland)

Metformin Hydrochloride, the active ingredient in Metformin Hydrochloride Taw Pharma (Ireland), is a biguanide presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults. GNH USA supplies Metformin Hydrochloride Taw Pharma (Ireland) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Hydrochloride is used primarily in the treatment of disorders related to glucose metabolism. - Type 2 diabetes mellitus: improves glycaemic control by lowering fasting and post‑prandial blood glucose levels.

Metformin Hydrochloride may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea. - Metallic taste in the mouth. - Decreased appetite. - Mild headache. - Weight loss: modest reduction in body weight.

Serious or Rare Side Effects: - Lactic acidosis: a rare but potentially fatal metabolic complication. - Severe hypoglycaemia: usually when combined with other glucose‑lowering agents. - Hepatic dysfunction: elevated liver enzymes. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Vitamin B12 deficiency: long‑term therapy may reduce absorption.

Metformin Hydrochloride requires careful consideration of patient‑specific factors before initiation. - Renal function: assess creatinine clearance; avoid in severe renal impairment. - Hepatic disease: use with caution; monitor liver enzymes. - Cardiovascular status: consider in patients with unstable heart failure. - Alcohol intake: limit consumption to reduce risk of lactic acidosis. - Pregnancy and lactation: safety not established; evaluate risk‑benefit. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Metformin Hydrochloride can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Certain antiretrovirals (e.g., dolutegravir): may increase metformin levels.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and potassium. - Beta‑blockers: may mask hypoglycaemia symptoms. - Proton pump inhibitors: occasional increase in metformin exposure. - Thyroid hormones: may require dose adjustment of metformin.